



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Richard E. Davis

Chief Financial Officer

Recent News

Monday, March 23, 2020 - 07:50 AM

[Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain](#)

Wednesday, March 18, 2020 - 04:24 PM

[Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th](#)

Wednesday, March 04, 2020 - 07:50 AM

[Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons \(SAGES\) 2020 Annual Meeting on April 2, 2020](#)

Monday, March 02, 2020 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference](#)

Wednesday, January 08, 2020 - 07:50 AM

Contact Information

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$0.21
Volume	63.87k
Shares Outstanding	187,862,947
Market Cap	\$38.51m
52 Week High	\$0.43
52 Week Low	\$0.12

as of 04/01/2020

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.